Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 2, 2020
Daily News
June 2, 2020
- Torii, ASKA to Copromote Riona for Iron Deficiency Anemia
June 2, 2020
- 15 Drug Makers See 3.6% Negative Growth in Japan in FY2020 as Re-Pricing, Generic Entries Weigh: Jiho Tally
June 2, 2020
- Onivyde Now Available in Japan: Servier/Yakult
June 2, 2020
- Daiichi Sankyo to Test TROP2-Directed ADC plus Keytruda in NSCLC
June 2, 2020
- Takeda Launching Project to Gauge Parkinson’s Symptoms with Wearables, Telemedicine Platform
June 2, 2020
- Takeda Gets CHMP Backing for Takhzyro Pre-Filled Syringe
June 2, 2020
- Teva Takeda to Curb Reminyl Generic Supply following June Listing due to India Lockdown
June 2, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…